New hope for pancreatic cancer: experimental drug combo enters human trials
NCT ID NCT07114861
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding two experimental drugs (KN510 and KN713) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with advanced pancreatic cancer that cannot be removed by surgery. About 30 adults aged 19–75 who have not had prior chemo for advanced disease will take part. The study will first find the best dose, then expand to see how well the combination controls tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KN510713 (two experimental drugs) plus mFOLFIRINOX chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for advanced pancreatic cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The experimental drugs could cause side effects or fail to improve outcomes over standard chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center
RECRUITINGGoyang-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••